Hypoxemic respiratory failure following ruxolitinib discontinuation in allogeneic hematopoietic cell transplantation recipients - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34272781/
Ruxolitinib, a selective inhibitor of Janus kinases 1 and 2, is increasingly being used in allogeneic hematopoietic cell transplantation (HCT) recipients, following its approval by the US Food and Drug...
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34260836/
Among patients with glucocorticoid-refractory or -dependent chronic GVHD, ruxolitinib led to significantly greater overall response, failure-free survival, and symptom response. The incidence of thrombocytopenia and anemia was greater with ruxolitinib....
-
Naveed Saleh, MD, MS – Skipta Team4yrKey Points • Conclusion/Relevance: “Among patients with glucocorticoid-refractory or -dependent chronic GVHD, ruxolitinib led to significantly greater overall response, failure-free survival, and symptom response. The incidence of thrombocytopenia and anemia was Show More
Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34184542/
Aim: Graft-versus-host disease (GvHD) is a major complication arising in patients undergoing allogenic hematopoietic stem cell transplantation. Material & methods: We tested ruxolitinib (a selective JAK1/2 inhibitor) efficacy in three...
Biomarker profile predicts clinical efficacy of extracorporeal photopheresis in steroid-resistant acute and chronic graft-vs-host disease after allogenic hematopoietic stem cell transplant - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34185332/
We conducted a multicenter interventional study to assess the efficacy of Therakos ECP to treat steroid-resistant graft-vs-host disease (SRes-GVHD) after allogeneic HSCT and to identify biomarkers of GVHD response. A...
Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34254289/
Ruxolitinib for steroid-refractory acute graft-versus-host disease (SR-aGVHD) results in resistance or intolerance in 1/5 of patients. Outcomes of such patients are undefined. We identified these patients in a multicentre review...